Ilaris® Approved By FDA To Treat Active Systemic Juvenile Idiopathic Arthritis, A Serious Form Of Childhood Arthritis
Ilaris® (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection1...
If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!